MarketCap
Facebook
X
Telegram
DexCom Market Cap | DXCM
As of September 09, 2026 DexCom has a market cap of $ 33 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.5 B | 25.7 B | 48.8 B | 42.1 B | 51.9 B | 34.9 B | 21.8 B | 12.7 B | 5.12 B | 6.57 B | 5.69 B | 4.5 B | 2.79 B | 1.03 B | 721 M | 139 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 51.9 B | 139 M | 18.1 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Neuronetics
STIM
|
81.1 M | $ 2.93 | 1.74 % | $ 193 M |  USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 603.02 | 0.02 % | $ 227 B | USA |
 |
Twist Bioscience Corporation
TWST
|
1.56 B | $ 128.06 | 2.68 % | $ 7.66 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 9.33 | 5.97 % | $ 389 M | USA |
 |
Sotera Health Company
SHC
|
4.75 B | $ 18.59 | 0.05 % | $ 5.28 B | USA |
 |
VolitionRx Limited
VNRX
|
25.2 M | $ 0.33 | 2.52 % | $ 41.5 M |  Singapore |
 |
Waters Corporation
WAT
|
19.7 B | $ 402.91 | 0.33 % | $ 24 B | USA |
 |
Exagen
XGN
|
70.1 M | $ 7.3 | 0.53 % | $ 157 M | USA |
 |
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
194 M | $ 9.06 | 0.64 % | $ 3.25 B |  Irlanda |
 |
Accelerate Diagnostics
AXDX
|
4.03 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
237 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 235.5 | 0.06 % | $ 26.1 B | USA |
 |
Syneos Health
SYNH
|
9.41 B | - | - | $ 4.46 B | USA |
 |
T2 Biosystems
TTOO
|
7.78 M | - | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
1.38 B | - | - | $ 1.49 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K |  Israel |
 |
Brainsway Ltd.
BWAY
|
301 M | $ 14.16 | 0.07 % | $ 481 M | Israel |
 |
Renalytix AI plc
RNLX
|
22.7 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Quidel Corporation
QDEL
|
10.6 B | $ 13.38 | 0.29 % | $ 564 M | USA |
 |
Precipio
PRPO
|
38.4 M | $ 27.25 | 0.11 % | $ 43.7 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M | Britain |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.9 | 0.66 % | $ 94.1 K | USA |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
|
Biodesix
BDSX
|
113 M | $ 26.63 | 1.72 % | $ 201 M | USA |
 |
Biomerica
BMRA
|
6.09 M | $ 2.34 | 1.3 % | $ 6.82 M | USA |
 |
BioNano Genomics
BNGO
|
7.95 M | $ 1.2 | 1.25 % | $ 6.53 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 10.71 | 11.22 % | $ 113 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Agilent Technologies
A
|
31.5 B | $ 146.85 | 0.59 % | $ 41.7 B | USA |
|
Centogene N.V.
CNTG
|
10.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
304 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
133 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
404 M | - | 0.12 % | $ 80.1 M | China |
 |
Bioventus
BVS
|
608 M | $ 13.83 | 0.42 % | $ 921 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 50.31 | 2.05 % | $ 2.68 B | USA |
 |
Celcuity
CELC
|
5.37 B | $ 93.02 | 0.75 % | $ 4.35 B | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.12 | 2.55 % | $ 1.49 M | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 280.76 | 0.54 % | $ 13.9 B | USA |
 |
Castle Biosciences
CSTL
|
472 M | $ 32.76 | 1.03 % | $ 950 M | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 205.23 | 0.53 % | $ 146 B | USA |
 |
DarioHealth Corp.
DRIO
|
32.8 M | $ 7.03 | 3.72 % | $ 28 M | Israel |
 |
Fulgent Genetics
FLGT
|
527 M | $ 20.2 | 2.38 % | $ 622 M | USA |